Doc, while I agree with you, I don't expect NWBO to say anything until something official comes out of the UK. While I believe it's looking like the EDEN is now a part of the total package, we'll only know that for certain when something official is announced from the UK.
If in fact the EDEN is included, it's also very possible that it's what's holding up the approval. As I see it, it's not an essential part of the approval if the label is just for GBM as the 20 tiny cleanrooms should meet the initial demand, but if the label is to be tumor agnostic, then they'd be totally overwhelmed without the EDEN.
I certainly don't know that I'll be proven right, but I still believe the hints coming out of the UK say that it's all going to be in the package. If it is, then the question becomes, were the other regulators involved, and is this truly going to be a multi-national approval?
I'm not saying this is the case, but if it were, I suspect a 100 banger this year, or sooner, is not out of the picture from todays prices.
Gary
Bullish
Market Data 
Markets 
AI
